Comparator supply for NCT07426757
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Sponsor: Pfizer (INDUSTRY). Phase: PHASE1. Status: Recruiting. Countries: United States, Canada. Last update posted 2026-09-04.
Registry record: https://clinicaltrials.gov/study/NCT07426757.
Canadian-labelled midazolam
9 marketed Canadian product(s) from 5 manufacturer(s) contain midazolam. Available strengths: 1 MG, 5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled midazolam as a trial comparator?
Yes. We source Canadian-marketed midazolam under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT07426757.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1-431-588-9055.